Recurrent triple-negative breast cancer (TNBC) tissues contain a higher amount of phosphatidylcholine (32:1) than non-recurrent TNBC tissues

被引:35
|
作者
Hosokawa, Yuko [1 ,2 ,3 ]
Masaki, Noritaka [2 ,3 ]
Takei, Shiro [2 ,3 ]
Horikawa, Makoto [2 ,3 ]
Matsushita, Shoko [2 ,3 ]
Sugiyama, Eiji [2 ,3 ]
Ogura, Hiroyuki [1 ]
Shiiya, Norihiko [1 ]
Setou, Mitsutoshi [2 ,3 ,4 ,5 ,6 ]
机构
[1] Hamamatsu Univ, Sch Med, Dept Surg 1, Higashi Ku, Hamamatsu, Shizuoka, Japan
[2] Hamamatsu Univ, Sch Med, Int Mass Imaging Ctr, Higashi Ku, Hamamatsu, Shizuoka, Japan
[3] Hamamatsu Univ, Sch Med, Dept Cellular & Mol Anat, Higashi Ku, Hamamatsu, Shizuoka, Japan
[4] Preeminent Med Photon Educ & Res Ctr, Higashi Ku, Hamamatsu, Shizuoka, Japan
[5] Univ Hong Kong, Dept Anat, 6-F,William MW Mong Block,Sassoon Rd, Pokfulam, Hong Kong, Peoples R China
[6] RIKEN, Ctr Mol Imaging Sci, Chuo Ku, Kobe, Hyogo, Japan
来源
PLOS ONE | 2017年 / 12卷 / 08期
关键词
MASS-SPECTROMETRY; SURVIVAL;
D O I
10.1371/journal.pone.0183724
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Triple-negative breast cancer (TNBC) is one of the breast cancer subtype that displays a high risk of early recurrence and short overall survival. Improvement of the prognosis of patients with TNBC requires identifying a predictive factor of recurrence, which would make it possible to provide beneficial personalized treatment. However, no clinically reliable predictive factor is currently known. In this study, we investigated the predictive factor of recurrence in TNBC using matrix-assisted laser desorption/ionization-imaging mass spectrometry for lipid profiling of breast cancer specimens obtained from three and six patients with recurrent and non-recurrent TNBC, respectively. The signal for phosphatidylcholine (PC) (32:1) at m/z 732.5 was significantly higher in the recurrence group compared to the non-recurrence group (P = 0.024). PC (32:1) was more abundant in the cancer epithelial area than it was in the surrounding stroma, suggesting that abnormal lipid metabolism was associated with malignant transformation. Our results indicate PC (32:1) as a candidate predictive factor of TNBC recurrence. A future prospective study investigating whether personalized therapy based on PC (32:1) intensity improves the prognosis of patients with TNBC is recommended.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Prognostic and Clinical Significance of PD-L1, EGFR and Androgen Receptor (AR) Expression in Triple-Negative Breast Cancer (TNBC) Patients
    Medic-Milijic, Natasa
    Jovanic, Irena
    Nedeljkovic, Milica
    Markovic, Ivan
    Spurnic, Igor
    Milovanovic, Zorka
    Ademovic, Nejla
    Tomic, Tijana
    Tanic, Nasta
    Tanic, Nikola
    LIFE-BASEL, 2024, 14 (06):
  • [42] Extracellular vesicle-derived non-coding RNAs to predict outcome in patients with triple-negative breast cancer (TNBC) with residual disease (RD).
    Stecklein, Shane R.
    Koestler, Devin
    Yellapu, Nanda K.
    Yoder, Rachel
    Kimler, Bruce F.
    Staley, JoshuaM.
    Schmitt, Zachary
    Khan, Qamar J.
    O'Dea, Anne
    Nye, Lauren Elizabeth
    Elia, Manana
    Heldstab, Jaimie
    Home, Trisha
    Hyter, Stephen
    Isakova, Kamilla
    Pathak, Harsh B.
    Godwin, Andrew K.
    Sharma, Priyanka
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] Expression of LXR-β, ABCA1 and ABCG1 in human triple-negative breast cancer tissues
    Pan, Hailing
    Zheng, Yue
    Pan, Qi
    Chen, Honglei
    Chen, Fuchun
    Wu, Jie
    Di, Dingxin
    ONCOLOGY REPORTS, 2019, 42 (05) : 1869 - 1877
  • [44] IGF-1/IGF-1R/FAK/YAP Transduction Signaling Prompts Growth Effects in Triple-Negative Breast Cancer (TNBC) Cells
    Rigiracciolo, Damiano Cosimo
    Nohata, Nijiro
    Lappano, Rosamaria
    Cirillo, Francesca
    Talia, Marianna
    Scordamaglia, Domenica
    Gutkind, J. Silvio
    Maggiolini, Marcello
    CELLS, 2020, 9 (04)
  • [45] Single-cell spatial analysis by imaging mass cytometry and immunotherapy response in triple-negative breast cancer (TNBC) in the NeoTRIPaPDL1 trial
    Bianchini, Giampaolo
    Wang, Xiao Qian
    Danenberg, Esther
    Huang, Chiun-Sheng
    Egle, Daniel
    Callari, Maurizio
    Bermejo, Begona
    Zamagni, Claudio
    Thill, Marc
    Anton, Anton
    Dugo, Matteo
    Zambelli, Stefania
    Russo, Stefania
    Ciruelos, Eva Maria
    Greil, Richard
    Semiglazov, Vladimir
    Colleoni, Marco
    Kelly, Catherine
    Mariani, Gabriella
    Del Mastro, Lucia
    Gyorffy, Balazs
    Biasi, Olivia
    Valagussa, Pinuccia
    Viale, Giuseppe
    Gianni, Luca
    Ali, H. Raza
    CANCER RESEARCH, 2022, 82 (04)
  • [46] High prevalence of BRCA1/2 germline mutations in female breast cancer patients with triple-negative phenotype (TNBC) and family history.
    Saura, C.
    Saanchez-Olle, G.
    Bosch, N.
    Gadea, N.
    Mesas, M.
    Tenes, A.
    Gutierrez-Enriquez, S.
    Diez, O.
    Baselga, J.
    Balmanna, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] H3K27me3-mediated regulation of PD-L1 expression in triple-negative breast cancer (TNBC)
    Harada, Jotaro
    Kawashima, Kei
    Matsubara, Yuka
    Oshi, Masanori
    Sasamoto, Mahato
    Yamada, Akimitsu
    Suganuma, Nobuyasu
    Fujii, Satoshi
    PATHOLOGY RESEARCH AND PRACTICE, 2025, 269
  • [48] Digital spatial profiling of immune-related proteins in luminal androgen receptor (LAR) vs non-LAR triple-negative breast cancer (TNBC)
    Leon-Ferre, Roberto A.
    Carter, Jodi M.
    Zahrieh, David M.
    Hillman, David W.
    Chumsri, Saranya
    Ma, Yaohua
    Kachergus, Jennifer M.
    Wang, Xue
    Boughey, Judy C.
    Liu, Minetta C.
    Ingle, James N.
    Kalari, Krishna R.
    Bisneto, Jose C. Villasboas
    Couch, Fergus J.
    Thompson, E. Aubrey
    Goetz, Matthew P.
    CANCER RESEARCH, 2022, 82 (04)
  • [49] Dose-finding combination study of niraparib and pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or recurrent platinum-resistant epithelial ovarian cancer (OC) (TOPACIO/Keynote-162)
    Konstantinopoulos, P. A.
    Sachdev, J. C.
    Schwartzberg, L.
    Matulonis, U. A.
    Sun, P.
    Wang, J. Y.
    Guo, W.
    Bobilev, D.
    Aktan, G.
    Karantza, V.
    Dezube, B.
    Vinayak, S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [50] Comparison study of different programmed death-ligand 1 (PD-L1) assays, readers and scoring methods in triple-negative breast cancer (TNBC)
    Noske, A.
    Wagner, D-C.
    Schwamborn, K.
    Foersch, S.
    Steiger, K.
    Kiechle, M.
    Karapetyan, S.
    Oettler, D.
    Hapfelmeier, A.
    Roth, W.
    Weichert, W.
    ANNALS OF ONCOLOGY, 2021, 32 : S26 - S26